Document Detail


Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
MedLine Citation:
PMID:  22571408     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P < 0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P < 0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P < 0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321.).
Authors:
Gian Luca Forni; Silverio Perrotta; Andrea Giusti; Giovanni Quarta; Lorella Pitrolo; Maria Domenica Cappellini; Domenico Giuseppe D'Ascola; Caterina Borgna Pignatti; Paolo Rigano; Aldo Filosa; Giovanni Iolascon; Bruno Nobili; Marina Baldini; Alessandra Rosa; Valeria Pinto; Ernesto Palummeri
Related Documents :
12186458 - Predictive value of serum prolactin levels measured immediately after transsphenoidal s...
6539698 - Human tumour ph changes following hyperthermia and radiation therapy.
10037248 - Long-term results of gh therapy in gh-deficient children treated before 1 year of age.
2694978 - Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial.
2028508 - Thymectomy in ulcerative colitis: a report of cases over a 13 year period.
18369068 - Retinal pigment epithelium (rpe)-choroid graft translocation in the treatment of an rpe...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-10
Journal Detail:
Title:  British journal of haematology     Volume:  -     ISSN:  1365-2141     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Centro della Microcitemia e delle Anemia Congenite - Ematologia, Ospedale Galliera, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clients' perspectives of rehabilitation in one acquired brain injury residential rehabilitation unit...
Next Document:  The Perceived Efficacy and Goal Setting System (PEGS), Part II: Evaluation of test-retest reliabilit...